Aclaris Therapeutics, Inc.
ACRS
$1.57
$0.063.97%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -130.21M | -132.07M | -37.00M | -58.68M | -77.26M |
Total Depreciation and Amortization | 692.00K | 807.00K | 892.00K | 932.00K | 908.00K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 99.21M | 100.26M | -6.98M | -3.13M | -1.21M |
Change in Net Operating Assets | 17.99M | 10.92M | 25.19M | -3.58M | 4.78M |
Cash from Operations | -12.32M | -20.08M | -17.90M | -64.46M | -72.79M |
Capital Expenditure | -29.00K | -121.00K | -562.00K | -646.00K | -891.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -67.45M | -69.65M | 27.07M | 56.89M | 38.15M |
Cash from Investing | -67.48M | -69.77M | 26.50M | 56.24M | 37.26M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 80.03M | 80.03M | 907.00K | 890.00K | 27.63M |
Repurchase of Common Stock | -629.00K | -409.00K | -76.00K | -168.00K | -157.00K |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -5.09M | -5.09M | -826.00K | -826.00K | -826.00K |
Cash from Financing | 74.32M | 74.54M | 5.00K | -104.00K | 26.65M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -5.48M | -15.31M | 8.61M | -8.32M | -8.88M |